Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare PSA Screening Coverage Guidelines To Be Finalized By 2000

This article was originally published in The Gray Sheet

Executive Summary

Development by the Health Care Financing Administration of coverage guidelines for prostate-specific antigen screening under the Medicare program is taking a backseat to other provisions of the Balanced Budget Act with earlier deadlines, according to the agency.

You may also be interested in...



USPSTF Drops Opposition To Prostate Screening, Remains Skeptical

The U.S. Preventive Services Task Force will no longer recommend against routine prostate cancer screening, but cautions that the benefits have not been fully demonstrated

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel